Reprogramming astrocytes to halt neuronal decline in aging brains

Astrocytes, the brain's support cells that control neuronal metabolism and synapse formation, lose function with age and in neurodegenerative diseases like Alzheimer's. Researchers have now shown that modulating astrocyte behavior—via histone deacetylase inhibitors (iHDAC) or gene therapy—reverses cognitive decline in both aged animals and transgenic Alzheimer's models. The compound LASSBio-1911, an HDAC inhibitor, countered the toxic effects of amyloid-beta oligomers (AβOs) on astrocytes, reducing synaptic damage; meanwhile, overexpression of Hevin, an extracellular matrix protein secreted by astrocytes and critical for excitatory synapse formation, improved cognitive performance in aged wild-type mice and APP/PS1 transgenic models. Both interventions avoid broad suppression of astrocyte reactivity—which can be protective—and instead target restoration of specific functions, establishing a viable pharmacological and genetic pathway for neurodegeneration treatments centered on brain support cells.